Radiopharm Theranostics Limited (ASX:RAD – Get Free Report) insider Riccardo Canevari bought 684,787 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were bought at an average cost of A$0.03 ($0.02) per share, for a total transaction of A$19,858.82 ($12,411.76).
Radiopharm Theranostics Price Performance
Radiopharm Theranostics Company Profile
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.
Featured Articles
- Five stocks we like better than Radiopharm Theranostics
- How Can Investors Benefit From After-Hours Trading
- 5 Reasons DraftKings Stock Looks Promising in the New Year
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Cybersecurity Stocks: 1 Immediate Buy and 1 Dip Opportunity
- 10 Best Airline Stocks to Buy
- The Next 2 AI Winners Have Triple-Digit Upside Potential
Receive News & Ratings for Radiopharm Theranostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radiopharm Theranostics and related companies with MarketBeat.com's FREE daily email newsletter.
